We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
+9.66%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$89.3B
AUM Growth
+$8.23B
Cap. Flow
+$1.9B
Cap. Flow %
2.12%
Top 10 Hldgs %
24.87%
Holding
4,460
New
1,490
Increased
1,679
Reduced
1,235
Closed
38

Top Buys

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$60.1M
2
TSM icon
TSMC
TSM
+$59.1M
3
TSLA icon
Tesla
TSLA
+$56M
4
AAPL icon
Apple
AAPL
+$55.2M
5
AMZN icon
Amazon
AMZN
+$47.5M

Top Sells

Rank Stock Value
1
ACWX icon
iShares MSCI ACWI ex US ETF
ACWX
+$102M
2
EG icon
Everest Group
EG
+$27.4M
3
CVX icon
Chevron
CVX
+$25M
4
WFC icon
Wells Fargo
WFC
+$24.9M
5
CXT icon
Crane NXT
CXT
+$13.5M

Sector Composition

Rank Sector Weight
1 Technology 27.27%
2 Healthcare 12.98%
3 Financials 12.17%
4 Consumer Discretionary 11.18%
5 Industrials 9.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
DCBO
3876
Docebo
DCBO
$520M
$985 ﹤0.01%
+25
New +$905
GFL icon
3877
GFL Environmental
GFL
$15B
$970 ﹤0.01%
+25
New +$908
LITS
3878
Lite Strategy Inc
LITS
$31.6M
$802 ﹤0.01%
+122
New +$776
PPBT
3879
Purple Biotech
PPBT
$1.31M
$777 ﹤0.01%
+3
New +$1.08K
BNTC icon
3880
Benitec Biopharma
BNTC
$451M
$752 ﹤0.01%
+186
New +$709
VRN
3881
DELISTED
Veren
VRN
$740 ﹤0.01%
+110
New +$766
PASG icon
3882
Passage Bio
PASG
$14.1M
$736 ﹤0.01%
+39
New +$772
ORTX
3883
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$736 ﹤0.01%
+142
New +$724
BFRA
3884
DELISTED
Biofrontera AG American Depositary Shares
BFRA
$714 ﹤0.01%
+288
New +$714
APLT
3885
DELISTED
Applied Therapeutics
APLT
$696 ﹤0.01%
+544
New +$722
MTA
3886
Metalla Royalty & Streaming
MTA
$785M
$694 ﹤0.01%
+160
New +$764
FMTO
3887
DELISTED
Femto Technologies Inc. Common Stock
FMTO
0
SPRO icon
3888
Spero Therapeutics
SPRO
$73.5M
$664 ﹤0.01%
+458
New +$784
TNON icon
3889
Tenon Medical
TNON
$2.92M
$652 ﹤0.01%
+30
New +$3.15K
LEJU
3890
DELISTED
Leju Holdings Limited American Depositary Shares, each representing ten (10) Ordinary Shares
LEJU
$646 ﹤0.01%
+280
New +$606
ISPO
3891
DELISTED
Inspirato
ISPO
$644 ﹤0.01%
33
-918
-97% -$16.6K
IPHA
3892
Innate Pharma
IPHA
$167M
$643 ﹤0.01%
+205
New +$630
VET icon
3893
Vermilion Energy
VET
$1.68B
$622 ﹤0.01%
+50
New +$617
QNCX icon
3894
Quince Therapeutics
QNCX
$28.9M
$592 ﹤0.01%
+2
New +$623
TXMD icon
3895
TherapeuticsMD
TXMD
$24.2M
$576 ﹤0.01%
+140
New +$549
YQ
3896
17 Education & Technology Group
YQ
$19.5M
$549 ﹤0.01%
+117
New +$651
SPRC icon
3897
SciSparc
SPRC
$3.85M
0
CORR
3898
DELISTED
CorEnergy Infrastructure Trust, Inc.
CORR
$504 ﹤0.01%
+450
New +$497
BMTX
3899
DELISTED
BM Technologies, Inc.
BMTX
$503 ﹤0.01%
+169
New +$512
STG
3900
Sunlands Technology
STG
$47.5M
$498 ﹤0.01%
+135
New +$756

Similar funds

RhumbLine Advisers's Q2 2023 Portfolio in Review

As of Q2 2023, RhumbLine Advisers held 4,460 positions worth $89.3B, up 10% from $81B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

RhumbLine Advisers's Q2 2023 filing shows 1,490 new, 1,679 increased, 1,235 reduced and 38 closed positions. Its largest new stake was TSMC: 635,517 shares worth $64.1M. The largest sale was iShares MSCI ACWI ex US ETF, an estimated $102M.

By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Financials.

  • RhumbLine Advisers's largest Q2 2023 buy was TSMC: 635,517 shares worth $64.1M.
  • RhumbLine Advisers added most to Microsoft in Q2 2023, an estimated $60.1M increase.
  • RhumbLine Advisers's biggest Q2 2023 reduction was iShares MSCI ACWI ex US ETF, cutting an estimated $102M.
  • RhumbLine Advisers fully exited Everest Group in Q2 2023, selling an estimated $27.4M.
  • RhumbLine Advisers's ten largest holdings make up 25% of its $89.3B portfolio in Q2 2023.
  • RhumbLine Advisers opened 1,490 new positions and closed 38 in Q2 2023.
  • RhumbLine Advisers's portfolio value rose 10% quarter-over-quarter to $89.3B.

Based on RhumbLine Advisers's 13F filing for Q2 2023, filed 8 Aug 2023.